(Q43410223)

English

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

scientific article published on 6 April 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1 reference

ChEBI release 2020-05-28

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

Charles Erlichman

2

object named as

C Erlichman

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

M W Saif

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

T Dragovich

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D Mendelson

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D Toft

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

F Burrows

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C Storgard

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D Von Hoff

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

71

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1345-1355

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Hsp90: a specialized but essential protein-folding tool

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Unusual expression and localization of heat-shock proteins in human tumor cells

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Heat shock protein and proteasome targeting agents

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Drug-induced prolongation of the QT interval

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Changes in the secretion of insulin-like growth factor binding proteins -2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Proliferation of DU145 prostate cancer cells is inhibited by suppressing insulin-like growth factor binding protein-2.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Hsp70 release from peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2134-9

21 January 2018

Identifiers

10.1007/S00280-013-2134-9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43410223&oldid=2206020998"